uniQure N.V. (QURE)
uniQure N.V. (QURE) from its SEC filings: 2025 revenue $16.1 million (-41% vs the year before), net margin -1236%, free cash flow -$178.4 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $16.1 million |
| Revenue growth | -41% |
| Net income | -$199.0 million |
| Net margin | -1236.2% |
| Free cash flow | -$178.4 million |
| Diluted EPS | $-3.46 |
| Latest quarter (Q1 2026 (calendar)) revenue vs a year earlier | +127% |
| Cash | $140.0 million |
| Long-term debt | $49.9 million |
| Share count, 1 year | +15% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.